Další formáty:
BibTeX
LaTeX
RIS
@article{1407639,
author = {Szturz, Petr and Budíková, Marie and Vermorken, Jan B. and Horová, Ivanka and Gál, Břetislav and Raymond, Eric and Gramont, A. de and Faivre, Sandrine},
article_location = {AMSTERDAM},
article_number = {NOV 2017},
doi = {http://dx.doi.org/10.1016/j.oraloncology.2017.09.009},
keywords = {c-MET receptor; Head and neck cancer; Immunohistochemistry; Overexpression; Prognostic factor; Predictive factor},
language = {eng},
issn = {1368-8375},
journal = {Oral oncology},
title = {Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data},
volume = {74},
year = {2017}
}
TY - JOUR
ID - 1407639
AU - Szturz, Petr - Budíková, Marie - Vermorken, Jan B. - Horová, Ivanka - Gál, Břetislav - Raymond, Eric - Gramont, A. de - Faivre, Sandrine
PY - 2017
TI - Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
JF - Oral oncology
VL - 74
IS - NOV 2017
SP - 68-76
EP - 68-76
PB - ELSEVIER SCIENCE BV
SN - 13688375
KW - c-MET receptor
KW - Head and neck cancer
KW - Immunohistochemistry
KW - Overexpression
KW - Prognostic factor
KW - Predictive factor
N2 - Objectives: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. Methods: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables. Results: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p < 1.0 x 10(-6)). Above cut-off level II, c-MET positivity was associated with worse overall survival (p = 4.0 x 10(-6)), positive nodal status (p = 1.0 x 10(-4)), higher disease stage (p = 7.0 x 10(-4)), older age (p = 2.1 x 10(-3)), disease recurrence (p = 2.0 x 10(-2)), and primary tumour localization in the oral cavity (p = 2.3 x 10(-2)). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p = 9.0 x 10(-6)), p16 negativity ( p = 2.4 x 10(-4)), worse overall survival (p = 4.0 x 10(-4)), positive epidermal growth factor receptor (EGFR) status (p = 7.2 x 10(-4)), and larger primary tumours (p = 4.6 x 10(-3)). Conclusion: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.
ER -
SZTURZ, Petr, Marie BUDÍKOVÁ, Jan B. VERMORKEN, Ivanka HOROVÁ, Břetislav GÁL, Eric RAYMOND, A. de GRAMONT a Sandrine FAIVRE. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. \textit{Oral oncology}. AMSTERDAM: ELSEVIER SCIENCE BV, 2017, roč.~74, NOV 2017, s.~68-76. ISSN~1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2017.09.009.
|
